Study the Polymorphism of the Calpain 10 Gene in Polycystic Ovary Syndrome in Iraqi Women
Main Article Content
Abstract
Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder of reproductive-aged women, characterized by oligo-/anovulation, hyperandrogenism, and polycystic ovarian morphology, and frequently accompanied by insulin resistance. Calpain-10 (CAPN10) regulates insulin secretion and glucose homeostasis, making it a plausible candidate gene for PCOS susceptibility. This case–control study examined the CAPN10 rs2975760 (T/C, UCSNP-44) polymorphism and serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and insulin in 20 women with PCOS and 20 age-matched controls in Iraq. Genotyping used allele-specific PCR; hormones were measured by electrochemiluminescence immunoassay and ELISA; diagnostic performance was assessed by receiver-operating characteristic (ROC) analysis. The wild-type TT genotype was more frequent in controls (85% vs 60%), the heterozygous TC genotype was more frequent in patients (30% vs 15%; OR = 2.83; P = 0.184), and the CC genotype was observed only in patients (10% vs 0%). The C allele was over-represented in patients (OR = 4.11; 95% CI 1.04–16.29; P = 0.034) by χ² but not by Fisher’s exact test (P = 0.066). FSH, LH, and insulin were all higher in patients (P < 0.01). Areas under the curve were 0.734 for FSH and 0.751 for LH—both only fair—whereas insulin appeared to separate the groups, most likely reflecting the small sample rather than a genuine diagnostic property. Among patients, TC carriers had higher LH, FSH, and insulin than TT carriers (P < 0.05). These hypothesis-generating findings are consistent with an association between CAPN10 rs2975760 and PCOS in Iraqi women, possibly mediated through insulin resistance, but require confirmation in larger cohorts.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
[1] Karkera, S.; Agard, E.; Sankova, L. The Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and the Treatment Options. Eur. J. Biol. Med. Sci. Res. 2023, 11(1), 57–91. https://doi.org/10.37745/ejbmsr.2013/vol11n15791
[2] Kicińska, A. M.; Maksym, R. B.; Zabielska-Kaczorowska, M. A.; Stachowska, A.; Babińska, A. Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome. Biomedicines 2023, 11(6), 1567. https://doi.org/10.3390/biomedicines11061567
[3] Diamanti-Kandarakis, E.; Kouli, C. R.; Bergiele, A. T.; et al. A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. J. Clin. Endocrinol. Metab. 1999, 84(11), 4006–4011. https://doi.org/10.1210/jcem.84.11.6148
[4] Escobar-Morreale, H. F.; Asunción, M.; Calvo, R. M.; et al. Receiver Operating Characteristic Analysis of the Performance of Basal Serum Hormone Profiles for the Diagnosis of Polycystic Ovary Syndrome. Eur. J. Endocrinol. 2000, 143(4), 501–508.
[5] Peña, A. S.; Witchel, S. F.; Hoeger, K. M.; Oberfield, S. E.; Vogiatzi, M. G.; Misso, M.; Garad, R.; Dabadghao, P.; Teede, H. Adolescent Polycystic Ovary Syndrome According to the International Evidence-Based Guideline. BMC Med. 2020, 18, 72. https://doi.org/10.1186/s12916-020-01516-x
[6] Bozdag, G.; Mumusoglu, S.; Zengin, D.; Karabulut, E.; Yildiz, B. O. The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hum. Reprod. 2016, 31(12), 2841–2855. https://doi.org/10.1093/humrep/dew218
[7] Çoban, Ö. G.; Tulacı, Ö. D.; Adanır, A. S.; Önder, A. Psychiatric Disorders, Self-Esteem, and Quality of Life in Adolescents with Polycystic Ovary Syndrome. J. Pediatr. Adolesc. Gynecol. 2019, 32(6), 600–604. https://doi.org/10.1016/j.jpag.2019.07.008
[8] Guo, J.; Lin, B.; Niu, R.; et al. Fat-Free Mass Index Is a Feasible Predictor of Insulin Resistance in Women with Polycystic Ovary Syndrome: Evidence from a Cross-Sectional Study. Endocrine 2024, 84(2), 420–426. https://doi.org/10.1007/s12020-023-03591-5
[9] Mayer, S. B.; Evans, W. S.; Nestler, J. E. Polycystic Ovary Syndrome and Insulin: Our Understanding in the Past, Present and Future. Womens Health (Lond.) 2015, 11(2), 137–149. https://doi.org/10.2217/WHE.14.73
[10] urwar, A.; Nagpure, S. Insulin Resistance in Polycystic Ovarian Syndrome. Cureus 2022, 14 (10), e30351. https://doi.org/10.7759/cureus.30351
[11] Ding, H.; Zhang, J.; Zhang, F.; et al. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front. Endocrinol. 2021, 12, 741764. https://doi.org/10.3389/fendo.2021.741764
[12] Livadas, S.; Anagnostis, P.; Bosdou, J. K.; Bantouna, D.; Paparodis, R. Polycystic Ovary Syndrome and Type 2 Diabetes Mellitus: A State-of-the-Art Review. World J. Diabetes 2022, 13(1), 5–26. https://doi.org/10.4239/wjd.v13.i1.5
[13] Ehrmann, D. A. Insulin Resistance and Polycystic Ovary Syndrome. Curr. Diab. Rep. 2002, 2(1), 71–76. https://doi.org/10.1007/s11892-002-0061-y
[14] [14] Gonzalez, A.; Abril, E.; Roca, A.; et al. CAPN10 Alleles Are Associated with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2002, 87(8), 3971–3976. https://doi.org/10.1210/jcem.87.8.8793
[15] Atiomo, W.; Khalid, S.; Parameshweran, S.; Houda, M.; Layfield, R. Proteomic Biomarkers for the Diagnosis and Risk Stratification of Polycystic Ovary Syndrome: A Systematic Review. BJOG 2009, 116(2), 137–143. https://doi.org/10.1111/j.1471-0528.2008.02041.x
[16] Pratama, G.; Wiweko, B.; Asmarinah; et al. Mechanism of Elevated LH/FSH Ratio in Lean PCOS Revisited: A Path Analysis. Sci. Rep. 2024, 14, 8229. https://doi.org/10.1038/s41598-024-58064-0
[17] Lakkakula, B. V. K. S.; Thangavelu, M.; Godla, U. R. Genetic Variants Associated with Insulin Signaling and Glucose Homeostasis in the Pathogenesis of Insulin Resistance in Polycystic Ovary Syndrome: A Systematic Review. J. Assist. Reprod. Genet. 2013, 30(7), 883–898. https://doi.org/10.1007/s10815-013-0030-1
[18] Horikawa, Y.; Oda, N.; Cox, N. J.; et al. Genetic Variation in the Gene Encoding Calpain-10 Is Associated with Type 2 Diabetes Mellitus. Nat. Genet. 2000, 26(2), 163–175. https://doi.org/10.1038/79876
[19] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33(6), 981–1030. https://doi.org/10.1210/er.2011-1034
[20] Miyazaki, T. Calpain and Cardiometabolic Diseases. Int. J. Mol. Sci. 2023, 24(23), 16782. https://doi.org/10.3390/ijms242316782
[21] Alageel, A. A.; Alshammary, A. F.; Ali Khan, I. Molecular Role of Non-Exonic Variants in CALPAIN 10 Gene in Polycystic Ovarian Syndrome in Saudi Women. Front. Endocrinol. 2023, 14, 1303747. https://doi.org/10.3389/fendo.2023.1303747
[22] Iwasaki, N.; Horikawa, Y.; Tsuchiya, T.; Kitamura, Y.; Nakamura, T.; Tanizawa, Y.; Oka, Y.; Hara, K.; Kadowaki, T.; Awata, T.; et al. Genetic Variants in the Calpain-10 Gene and the Development of Type 2 Diabetes in the Japanese Population. J. Hum. Genet. 2005, 50(2), 92–98. https://doi.org/10.1007/s10038-004-0225-5
[23] Zweig, M. H.; Campbell, G. Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine. Clin. Chem. 1993, 39(4), 561–577. https://doi.org/10.1093/clinchem/39.4.561
[24] Al-Murshedi, H. H.; Fadhil Jawad, A.; Al-Tu'ma, F. J.; Hadi, E. A.; Al-Tu'ma, M. M. K. Molecular Studies of CAPN-10 Gene (rs2975760) and Its Association with Insulin Resistance in Polycystic Ovarian Syndrome of Iraqi Women. J. Contemp. Med. Sci. 2022, 8(6), 382–387. https://doi.org/10.22317/jcms.v8i6.1298
[25] Li, Y.; Han, T.; Wang, Y.; Gao, J.; Zhang, J.; Wu, Y.; Luo, J. Association of Calpain10 Polymorphisms with Polycystic Ovarian Syndrome Susceptibility: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. Front. Genet. 2023, 14, 1153960. https://doi.org/10.3389/fgene.2023.1153960
[26] Alnakash, A. H.; Al-Tae'e, N. K. Polycystic Ovarian Syndrome: The Correlation between the LH/FSH Ratio and Disease Manifestations. Middle East Fertil. Soc. J. 2007, 12(1), 35–40.
[27] Löffler, S.; Aust, G.; Köhler, U.; Spanel-Borowski, K. Evidence of Leptin Expression in Normal and Polycystic Human Ovaries. Mol. Hum. Reprod. 2001, 7(12), 1143–1149. https://doi.org/10.1093/molehr/7.12.1143
[28] Dapas, M.; Lin, F. T. J.; Nadkarni, G. N.; et al. Distinct Subtypes of Polycystic Ovary Syndrome with Novel Genetic Associations: An Unsupervised, Phenotypic Clustering Analysis. PLoS Med. 2020, 17(6), e1003132. https://doi.org/10.1371/journal.pmed.1003132
[29] Fazli, D.; Moghaddasi, S. P. Correlations between Gonadotropin Hormones and the Manifestations of Polycystic Ovary Syndrome. Thrita J. Neu. 2022, 11(1), e117396. https://doi.org/10.5812/thrita-117396
[30] Shaalan, A. J.; Kadhem, M. W. Therapeutic Effects of Marjoram (Origanum majorana L.) Extract and Nano-Formulation on Hormonal Parameters and Ovarian Histology in Letrozole-Induced Polycystic Ovary Syndrome in Rats. ASEAN J. Sci. Technol. Rep. 2026, 29(6), e262149. https://doi.org/10.55164/ajstr.v29i6.262149
[31] Casteel, C. O.; Singh, G. Physiology, Gonadotropin-Releasing Hormone. In StatPearls; StatPearls Publishing: Treasure Island, FL, 2020.
[32] Blank, S. K.; McCartney, C. R.; Marshall, J. C. The Origins and Sequelae of Abnormal Neuroendocrine Function in Polycystic Ovary Syndrome. Hum. Reprod. Update 2006, 12(4), 351–361. https://doi.org/10.1093/humupd/dml017
[33] Franks, S.; Stark, J.; Hardy, K. Follicle Dynamics and Anovulation in Polycystic Ovary Syndrome. Hum. Reprod. Update 2008, 14(4), 367–378. https://doi.org/10.1093/humupd/dmn015
[34] Atoum, M. F.; Alajlouni, M. M.; Alzoughool, F. A Case-Control Study of the Luteinizing Hormone Level in Luteinizing Hormone Receptor Gene (rs2293275) Polymorphism in Polycystic Ovarian Syndrome Females. Public Health Genomics 2022, 25(1–2), 1–9. https://doi.org/10.1159/000521971
[35] Zhang, H.; Wang, W.; Zhao, J.; Jiao, P.; Zeng, L.; Zhang, H.; Zhao, Y.; Shi, L.; Hu, H.; Luo, L.; et al. Relationship between Body Composition, Insulin Resistance, and Hormonal Profiles in Women with Polycystic Ovary Syndrome. Front. Endocrinol. 2022, 13, 1085656. https://doi.org/10.3389/fendo.2022.1085656
[36] Bogari, N. M. Genetic Construction between Polycystic Ovarian Syndrome and Type 2 Diabetes. Saudi J. Biol. Sci. 2020, 27(10), 2539–2543. https://doi.org/10.1016/j.sjbs.2020.05.004
[37] Rahmatnezhad, L.; Moghaddam-Banaem, L.; Behroozi-Lak, T.; Shiva, A.; Rasouli, J. Association of Insulin Resistance with Polycystic Ovary Syndrome Phenotypes and Patients' Characteristics: A Cross-Sectional Study in Iran. Reprod. Biol. Endocrinol. 2023, 21(1), 113. https://doi.org/10.1186/s12958-023-01160-z
[38] Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr. Rev. 1997, 18(6), 774–800. https://doi.org/10.1210/er.18.6.774